Oral and Anal Swab Sampling in Patients With HPV Positivity

Evaluation of Oropharyngeal and Anal Swab Samples in Patients With HPV Positivity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06906913

Acronym

Oral Anal HPV

Enrollment

Registered

2025-04-02

Start date

2023-03-14

Completion date

2024-11-19

Last updated

2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV

Keywords

Anal, cervical, human papillomavirus, oropharyngeal, screening

Brief summary

Patients whose pathology results are reported as cervical intraepithelial neoplasia (CIN) 1, CIN 2, and CIN 3, are recruited. We aimed to evaluate HPV-positive women presenting to the Obstetrics and Gynecology clinic, whose cervical pathology results were reported as CIN 1, CIN 2, and CIN 3, by collecting oropharyngeal and anal swab samples. A total of 30 women of reproductive age, who consented to participate, were included in the study.

Detailed description

Human papillomavirus (HPV) positivity is associated with cervical, oropharyngeal, and anal cancers. There is insufficient data in the current literature regarding the effectiveness of obtaining oropharyngeal and anal swabs from patients with HPV positivity is an effective method for detecting potential pathologies. HPV-positive women presenting to the Obstetrics and Gynecology clinic, whose cervical pathology results were reported as CIN 1, CIN 2, and CIN 3, will be evaluated by collecting oropharyngeal and anal swab samples.

Interventions

DIAGNOSTIC_TESTHPV testing

Oropharyngeal and anal swab samples are evaluated in the Microbiology laboratory for the existence of HPV.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* HPV-positive women presenting to the Obstetrics and Gynecology clinic, whose cervical pathology results were reported as CIN 1, CIN 2, and CIN 3

Exclusion criteria

* HPV-negative women

Design outcomes

Primary

Measure	Time frame	Description
Oropharyngeal Swab Sample - HPV Testing	1 month	Presence of HPV will be tested
Anal Swab Sample - HPV Testing	1 month	Presence of HPV

Secondary

Measure	Time frame	Description
Oropharyngeal Swab Sample - HPV Testing (if positive)	1 month	Type of HPV
Anal Swab Sample - HPV Testing (if positive)	1 month	Type of HPV

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026